2009, Diabetes and Drug Development

AZ boasts phase 3 win for self-administered gMG drug

pharmaphorum

JULY 24, 2025

Skip to main content Thursday 24 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars

GSK adds EU to Blenrep checklist as FDA sets new PDUFA date

pharmaphorum

JULY 24, 2025

Skip to main content Thursday 24 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars

GRIN Therapeutics: Seeking to address unmet needs in rare neurodevelopmental disorders

pharmaphorum

JUNE 30, 2025

Skip to main content Monday 30 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes

Diabetes Pharmaceutical Companies Pharmaceutical Companies Drug Development

Why security-first design is the fix to stalling AI pilot tools

pharmaphorum

JULY 2, 2025

Skip to main content Wednesday 2 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes

Diabetes Pharmaceutical Companies Pharmaceutical Companies Drug Development

Update: Rumour confirmed as Lilly buys Verve Therapeutics

pharmaphorum

JUNE 17, 2025

billion takeover bid for Verve Therapeutics, upgrading a collaboration between the two companies that dates back to 2023. billion takeover bid for Verve Therapeutics, upgrading a collaboration between the two companies that dates back to 2023.

Diabetes

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars

Caris swells its planned IPO, seeking $5.7bn valuation

pharmaphorum

JUNE 17, 2025

Skip to main content Tuesday 17 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars

Unlocking the Potential of Targeting the Innate Immune System

pharmaphorum

JULY 17, 2025

Skip to main content Thursday 17 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Immunity

Immunity Immunization Diabetes Pharmaceutical Companies

8th Neuropsychiatric Drug Development Summit

pharmaphorum

JUNE 27, 2025

Skip to main content Friday 27 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Drug Development

Drug Development Diabetes Pharmaceutical Companies Pharmaceutical Companies

13th IMPACCT Real-World Evidence Summit

pharmaphorum

JUNE 24, 2025

Skip to main content Tuesday 24 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes

Diabetes Pharmaceutical Companies Pharmaceutical Companies Drug Development

The Obesity Drug Development Summit has landed in Europe!

pharmaphorum

JUNE 27, 2025

Skip to main content Friday 27 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Drug Development

Drug Development Diabetes Pharmaceutical Companies Pharmaceutical Companies

Most pharmas not ready for AI in customer engagement

pharmaphorum

JUNE 10, 2025

Skip to main content Tuesday 10 June 2025 twitter linkedin facebook rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars

Is India capable of ensuring equitable access to biopharmaceuticals?

Express Pharma

SEPTEMBER 6, 2023

According to the World Health Organisation (WHO), an estimated two billion people across the world do not have access to essential medicines for life threatening diseases like cancer, AIDS and even autoimmune diseases like Type 1 diabetes.

Insurance Coverage and Processing

Insurance Coverage and Processing Biosimilars Generic Medicine Drug Pricing

Frontiers Health Steering Committee spotlight – Paul Tunnah

pharmaphorum

OCTOBER 11, 2022

Instead, he shifted to consulting and, after a period of time, the launch of pharmaphorum in 2009. “[My] If you look at companies like Amazon and Google, the big tech companies, whenever they’ve gone into drug development on that side, they’ve found it incredibly hard. It’s very risky; it’s very hard to do.

Communication

Communication Diabetes Drug Development

Novo Nordisk slumps as it cuts sales forecast, names new CEO

pharmaphorum

JULY 29, 2025

Skip to main content Tuesday 29 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

MSD trims outlook as it aims to shave $3bn off costs

pharmaphorum

JULY 29, 2025

Skip to main content Tuesday 29 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Pharmacist Digest

AZ boasts phase 3 win for self-administered gMG drug

GSK adds EU to Blenrep checklist as FDA sets new PDUFA date

Trending Sources

GRIN Therapeutics: Seeking to address unmet needs in rare neurodevelopmental disorders

Why security-first design is the fix to stalling AI pilot tools

Update: Rumour confirmed as Lilly buys Verve Therapeutics

Caris swells its planned IPO, seeking $5.7bn valuation

Unlocking the Potential of Targeting the Innate Immune System

8th Neuropsychiatric Drug Development Summit

13th IMPACCT Real-World Evidence Summit

The Obesity Drug Development Summit has landed in Europe!

Most pharmas not ready for AI in customer engagement

Is India capable of ensuring equitable access to biopharmaceuticals?

Frontiers Health Steering Committee spotlight – Paul Tunnah

Novo Nordisk slumps as it cuts sales forecast, names new CEO

MSD trims outlook as it aims to shave $3bn off costs

Stay Connected